Ascendis Pharma is committed to developing a proprietary pipeline of unique products that address unmet patient needs in rare endocrine diseases. Our ongoing clinical trials for TransCon hGH and TransCon PTH are a reflection of that commitment.
|A phase 3 clinical trial comparing once-weekly TransCon hGH to daily hGH in eligible treatment-naïve, pre-pubertal children with GHD.
For more information visit heiGHtTrial.com.
|A phase 3 clinical trial of once-weekly TransCon hGH in GH treatment-experienced children with GHD.|